|
The Effectiveness of the Drug Uperio and Angiotensin-Converting Enzyme Inhibitors during Dilated Cardiomyopathy Complicated by Chronic Heart Failure
|
|
| Author:
|
ZALIM PANAGOV, ZUMURUD G. SAFAROVA, AL’BINA YU. SHERIEVA, ILONA R. GUDIEVA, ZAUR K.TSUKKIEV
|
| Abstract:
|
Introduction. One of the urgent problems in modern cardiology is the diagnosis of chronic heart failure (CHF) in the early stages of development and, therefore, improving the prognosis and quality of life of patients. The most significant reasons for the development of heart failure at a relatively young age include dilated cardiomyopathy (DCM), which manifests itself only with the development of heart failure. Clinical recommendations of recent decades dictate the need for the appointment of angiotensin-converting enzyme (ACE) inhibitors for the treatment of heart failure. In 2014, the results of a large randomized, double-blind clinical trial of PARADIGM-HF were published, during which the efficacy of standard therapy of heart failure with ACE inhibitors was compared with the new generation drug therapy Uperio.
The purpose of this study is to compare the effect of the drug Uperio and ACE inhibitors on the course of DCM complicated by heart failure, according to the level of NT-proBNP and the value of hemodynamic parameters.
Materials and methods. 32 patients with DCM complicated by heart failure were monitored in 2 groups: the main group (patients treated with Uperio) and the control group (patients treated with ACE inhibitors). Before the start of treatment and after its completion, an assessment of the clinical condition, an electrocardiographic and echocardiographic study, determination of the level of NT-proBNP in all patients were carried out.
Research results and conclusions. Therapy with a new generation of Uperio leads to a more significant improvement in the clinical condition of patients with DCM than ACE inhibitors, reducing the intensity of shortness of breath by 78.1 and 65.6%, respectively. A more effective decrease in the level of NT-proBNP (by 47 and 22%, respectively) and an increase in the ejection fraction (by 10.2 and 6.3%, respectively) by the time of discharge in the group of patients taking Uperio were observed compared with the group of patients taking inhibitors ACE.
|
| Keyword:
|
cardiomyopathy, heart failure, ejection fraction, efficacy, NT-proBNP, therapy.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.02.0065
|
| Download:
|
Request For Article
|
|
|